Clinical trials: Brentuximab
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
This phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory) that have been previously…
- Trial name
- NCT05039073
- Testing
- Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Emory University
Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with…
- Trial name
- NCT04213209
- Testing
- Brentuximab Vedotin (Genetical Recombination)
- Where
- Japan
- Volunteers
- 95 people
- Sponsor
- Takeda
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A).
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Trial name
- NCT01421667
- Testing
- brentuximab vedotin, rituximab
- Where
- 34 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Seagen Inc.
Hodgkin Lymphoma
Brentuximab for Newly Diagnosed Hodgkin Disease
The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
- Trial name
- NCT02398240
- Testing
- Brentuximab Vedotin, Doxorubicin, Vincristine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mitchell Cairo
Hodgkin Lymphoma
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur.
- Trial name
- NCT03646123
- Testing
- brentuximab vedotin, doxorubicin, vinblastine
- Where
- 76 sites in United States, Australia and 4 more
- Volunteers
- 255 people
- Sponsor
- Seagen Inc.
Hodgkin Lymphoma
BV-AVD-R Treatment Children Hodgkin's Lymphoma
The goal of this clinical trial is to use modified Brentuximab Vedotin+doxorubicin+vinblastine+dacarbazine+Rituximab(BV-AVD-R) regimen in Chinese Classical Hodgkin's Lymphoma(HL) children.
- Trial name
- NCT06201507
- Testing
- Brentuximab vedotin, Rituximab, Doxorubicin
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Beijing Children's Hospital
Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase I/II trial studies the side effects and the best dose of brentuximab vedotin when given together with gemcitabine hydrochloride and to see how well they work in treating younger patients with Hodgkin lymphoma that has…
- Conditions
- Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
- Trial name
- NCT01780662
- Testing
- Brentuximab Vedotin, Gemcitabine Hydrochloride
- Where
- 116 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase II trial studies how well ibrutinib and brentuximab vedotin work in treating patients with Hodgkin lymphoma that has returned (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT02744612
- Testing
- Brentuximab Vedotin, Ibrutinib
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- City of Hope Medical Center
Graft Versus Host Disease
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease
The purpose of this research is to test the safety and efficacy of brentuximab vedotin in patients with acute skin graft-versus-host disease (GVHD)
- Trial name
- NCT01616680
- Testing
- brentuximab vedotin, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Hodgkin Disease
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with…
- Trial name
- CheckMate 744 (NCT02927769)
- Testing
- Nivolumab, brentuximab vedotin, bendamustine
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.
- Conditions
- Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
- Trial name
- NCT00947856
- Testing
- brentuximab vedotin
- Where
- 17 sites in United States, France
- Volunteers
- 110 people
- Sponsor
- Seagen Inc.
Hodgkin Disease
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen…
- Trial name
- NCT02979522
- Testing
- Brentuximab vedotin, Doxorubicin, Vinblastine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 59 people
- Sponsor
- Takeda
Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
- Trial name
- NCT00866047
- Testing
- brentuximab vedotin
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 58 people
- Sponsor
- Seagen Inc.
Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
This phase I/II trial studies the side effects and best dose of ceritinib when given together with brentuximab vedotin to see how well they work in treating treatment-naive patients with anaplastic lymphoma kinase (ALK)-positive…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma
- Trial name
- NCT02729961
- Testing
- Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Washington
Untreated CD30-Positive Hodgkin's Lymphoma
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"
The purpose of this survey is to monitor and identify the occurrence of neutropenia and febrile neutropenia in untreated CD30-positive Hodgkin's lymphoma participants on concomitant brentuximab vedotin and doxorubicin…
- Trial name
- NCT03729609
- Testing
- Brentuximab vedotin (Genetical Recombination)
- Where
- Japan
- Volunteers
- 113 people
- Sponsor
- Takeda
Hodgkin Lymphoma
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma
The purpose of this study is to assess the efficacy of two three-weekly 1.8 mg/kg Brentuximab vedotin administrations in untreated patients with Hodgkin Lymphoma (HL).
- Trial name
- NCT02275598
- Testing
- Brentuximab vedotin, ABVD
- Where
- 3 sites in Italy
- Volunteers
- 12 people
- Sponsor
- University of Modena and Reggio Emilia
Lymphoma
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
This research is being done to study a combination of Brentuximab vedotin and Rituximab for the treatment of relapsed Hodgkin's Lymphoma (HL).
- Trial name
- NCT01900496
- Testing
- Brentuximab vedotin, Rituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger patients with stage IIB, IIIB or IV Hodgkin lymphoma.
- Conditions
- Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Trial name
- NCT01920932
- Testing
- brentuximab vedotin, etoposide, prednisone
- Where
- 6 sites in United States
- Volunteers
- 77 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.
- Trial name
- NCT01492088
- Testing
- Brentuximab vedotin
- Where
- 18 sites in United States, France and 6 more
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Hodgkin's Disease
An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded…
- Trial name
- CheckMate 436 (NCT02581631)
- Testing
- Nivolumab, Brentuximab Vedotin
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 145 people
- Sponsor
- Bristol-Myers Squibb